Dr. Marcus Gitterle Shares Emerging Wound Care Research at IPAWS/Tissue Repair Summit 2026
WoundCentrics Chief Medical Officer Marcus Gitterle, MD, presented three lectures at the 2026 International Post Acute Wound Care Summit (IPAWS) and Tissue Repair Summit (TRS), held September 10–11 in New Orleans, Louisiana. The summit convened wound care specialists and clinical leaders to share scientific findings, practical expertise, and emerging approaches to complex wound management.
Dr. Gitterle’s presentations addressed three important areas in wound care: calciphylaxis, diabetic foot ulcer diagnosis and treatment, and emerging clinical data involving FastSkin, an autologous blood patch designed to support wound healing in patients with diabetes.
Advancing calciphylaxis care
Calciphylaxis is a rare, deadly condition affecting up to 200,000 patients annually that is associated with painful skin lesions and a high risk of complications. During his presentation, Dr. Gitterle discussed new findings regarding the disease’s underlying mechanism, showing how a simple nutritional deficiency is key to its development and treatment.
The presentation focused on the potential for more targeted, treatable approaches to a condition that has historically been difficult to manage. Continued clinical research is essential to improving recognition, care planning, and outcomes for patients affected by complex and high-risk wounds and a core part of the WoundCentrics mission.
Closing gaps in diabetic foot ulcer care
Dr. Gitterle also presented emerging data on avoidable gaps in the diagnosis and treatment of diabetic foot ulcers. Timely identification, thorough assessment, coordinated treatment, and appropriate escalation of care are central to reducing complications that can lead to infection, hospitalization, and lower-extremity amputation.
For patients living with diabetes, a foot wound should never be dismissed as a minor issue. Early evaluation by qualified clinicians can help identify contributing factors, including infection, ischemia, pressure, neuropathy, and impaired healing, to allow a comprehensive treatment plan to begin as soon as possible.
Exploring autologous blood-based healing
In a third session, Dr. Gitterle shared findings from a recent clinical trial conducted by his team involving FastSkin, an autologous blood patch. The presentation examined data indicating that the therapy may improve wound-healing rates for patients with diabetes.
Autologous therapies use materials derived from the patient’s own blood. These approaches are being studied as potential additions to evidence-based wound care plans, particularly for hard-to-heal wounds where timely closure can help reduce complications and improve quality of life.
A commitment to wound care innovation
WoundCentrics is committed to advancing the science and delivery of wound care through clinical expertise, research, and education. Dr. Gitterle’s participation in IPAWS/TRS reflects that commitment and supports ongoing dialogue among clinicians working to improve outcomes for patients with complex wounds.
The IPAWS/Tissue Repair Summit is an international forum focused on the exchange of scientific data and clinical expertise in wound healing.
This article is intended for educational and informational purposes only and is not medical advice. Treatment decisions should be made by qualified healthcare professionals based on each patient’s individual clinical needs.